Increase in the turnover of brain dopamine by stimulation of muscarinic receptors outside the dopamine nerve terminals.
D015107:4-Butyrolactone / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001285:Atropine / Q000494:pharmacology; D001286:Atropine Derivatives / Q000494:pharmacology; D001921:Brain / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism* / Q000502:physiology; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D009411:Nerve Endings / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000378:metabolism; D010095:Oxotremorine / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D051381:Rats; D011950:Receptors, Cholinergic / Q000502:physiology*; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001286:Atropine Derivatives; D006834:Hydrazines; D011950:Receptors, Cholinergic; D011976:Receptors, Muscarinic; D010095:Oxotremorine; D001285:Atropine; D010830:Physostigmine; D001058:Apomorphine; D015107:4-Butyrolactone; D004298:Dopamine; D009638:Norepinephrine